Eli Lilly and Co. and Merck have entered another immuno-oncology collaboration to evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. Promising Phase I results offer the potential to progress to Phase II trials in metastatic breast cancer or non-small cell lung cancer (NSCLC). Lilly is sponsoring the Phase I study, and any subsequent Phase II studies. Enrollment...